首页> 外文期刊>International journal of gynecological pathology: Official journal of the International Society of Gynecological Pathologists >The distinction of clear cell carcinoma of the female genital tract, clear cell renal cell carcinoma, and translocation-associated renal cell carcinoma: an immunohistochemical study using tissue microarray.
【24h】

The distinction of clear cell carcinoma of the female genital tract, clear cell renal cell carcinoma, and translocation-associated renal cell carcinoma: an immunohistochemical study using tissue microarray.

机译:女性生殖道透明细胞癌,透明细胞肾细胞癌和易位相关性肾细胞癌的区别:使用组织芯片的免疫组织化学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Clear cell carcinoma of the female genital tract (CCCa) shares many histologic features with clear cell renal cell carcinoma (CCRCC) and translocation-associated renal cell carcinoma (TA-RCC), the latter in particular. When CCRCC or TA-RCC metastasizes to the female genital tract, or when patients have a history of both CCCa- and RCC-developed metastatic lesions, it is critical to distinguish the 3 lesions. Such a distinction is not always possible based on the morphology alone and often requires immunostains. We therefore investigated the utility of a panel of routinely used immunohistochemical markers including cytokeratin (CK) 7 and 20, CD10, alpha-methylacyl-CoA racemase, carbonic anhydrase IX (CA IX), TFE3, and WT-1 in the distinction of the 3 lesions on a tissue microarray of 12 CCCa, 5 TA-RCC, and 23 CCRCC cases. CK7 was positive in all CCCa cases, but only in 20% of TA-RCCs and 4.3% of CCRCCs. In contrast, CD10 was positive in all TA-RCCs and 91.3% of CCRCCs, but in only 7.5% of CCCa cases. TFE3 was positive in all TA-RCCs, but negative in all CCCa and CCRCC cases. CA IX was positive in 87% of CCRCCs, but in only 20% of TA-RCCs, and was negative in all CCCa cases. CK20, alpha-methylacyl-CoA racemase, and WT-1 were not contributory to the distinction. Although morphologically similar, CCCa can be reliably distinguished from TA-RCC and CCRCC. CCCa is mostly CK7/CD10/CA IX/TFE3, TA-RCC is usually CK7/CD10/CA IX/TFE3, whereas CCRCC is mostly CK7/CD10/CA IX/TFE3. To the best of our knowledge, this was the first study to directly compare the immunophenotypes of these 3 lesions.
机译:女性生殖道透明细胞癌(CCCa)与透明细胞肾细胞癌(CCRCC)和易位相关性肾细胞癌(TA-RCC)具有许多组织学特征,尤其是后者。当CCRCC或TA-RCC转移到女性生殖道时,或者当患者同时具有CCCa和RCC形成的转移性病变史时,区分这3个病变至关重要。仅基于形态学,这种区分并不总是可能的,并且经常需要免疫染色。因此,我们研究了一组常用的免疫组织化学标记物的用途,包括细胞角蛋白(CK)7和20,CD10,α-甲基酰基辅酶A消旋酶,碳酸酐酶IX(CA IX),TFE3和WT-1,以区分12例CCCa,5例TA-RCC和23例CCRCC的组织芯片上有3个病变。 CK7在所有CCCa病例中均为阳性,但仅在20%的TA-RCC和4.3%的CCRCC中为阳性。相比之下,所有TA-RCC和91.3%的CCRCC中CD10均为阳性,而CCCa病例仅为7.5%。 TFE3在所有TA-RCC中均为阳性,但在所有CCCa和CCRCC病例中均为阴性。 CA IX在87%的CCRCC中呈阳性,但在仅20%的TA-RCC中呈阳性,在所有CCCa病例中均为阴性。 CK20,α-甲基酰基辅酶A消旋酶和WT-1对此无贡献。尽管在形态上相似,但是可以可靠地将CCCa与TA-RCC和CCRCC区分开。 CCCa通常是CK7 / CD10 / CA IX / TFE3,TA-RCC通常是CK7 / CD10 / CA IX / TFE3,而CCRCC通常是CK7 / CD10 / CA IX / TFE3。据我们所知,这是第一个直接比较这3种病变的免疫表型的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号